Učitavanje...
Nivolumab and Ipilimumab versus Ipilimumab in Untreated Melanoma
BACKGROUND: In a phase 1 dose-escalation study, combined inhibition of T-cell checkpoint pathways by nivolumab and ipilimumab demonstrated a high objective response rate, including complete responses in patients with advanced melanoma. METHODS: In this double-blind study, 142 treatment-naïve patient...
Spremljeno u:
| Izdano u: | N Engl J Med |
|---|---|
| Glavni autori: | , , , , , , , , , , , , , , , , , , , , |
| Format: | Artigo |
| Jezik: | Inglês |
| Izdano: |
2015
|
| Teme: | |
| Online pristup: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5744258/ https://ncbi.nlm.nih.gov/pubmed/25891304 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1056/NEJMoa1414428 |
| Oznake: |
Dodaj oznaku
Bez oznaka, Budi prvi tko označuje ovaj zapis!
|